3D Workstation Visualizes Thrombi Previously Not Seen with Traditional Imaging Technology

New technology provides a groundbreaking, three-dimensional (3D) visualization tool that could enable a virtual angioscopy of the inside of cardiac structures using noninvasive computed tomography (CT) scanning.

Intrinsic Medical Imaging (Bloomfield, MI, USA), a developer of 3D medical imaging software, reported it has received US Food and Drug Administration (FDA) premarket notification clearance for its groundbreaking IMI Spectrum 3D imaging workstation (K121023). The company’s next-generation 3D capabilities will provide visualization and quantification tools designed to overcome errors, inconsistencies, and challenges associated with evaluating images utilizing existing conventional 2D and 3D methods.

“Intrinsic provides revolutionary, advanced 3D visualization which could enable a virtual angioscopy of the inside of cardiac structures through a simple, noninvasive CT scan,” said Arie Blitz, MD, director, Heart Transplantation and Mechanical Circulatory Support, University Hospitals Case Medical Center (Cleveland, OH, USA). “For example, we processed a patient’s standard 2D CT images using the IMI technology and saw thrombi in 3D previously undetected in 2D. This is amazing technology.”

Intrinsic employs uncompressed rendering techniques that preserve the integrity of the data from 2D to 3D, while enabling the user to navigate in real time, anywhere in the volume, while allaying visual artifacts and creating a more natural and user-friendly environment.

High-performance algorithms process more than 100 times more operations per second than existing 3D systems, creating an order-of-magnitude improvement in spatial resolution and image detail over existing standards. The IMI Spectrum 3D image visualization platform provides clinicians with diagnostic, planning, and treatment solutions to boost clinical effectiveness and speed the objective of saving lives.

“Receipt of this clearance is a significant step for our company and we look forward to improving patient outcomes while reducing unnecessary healthcare expenditures through the introduction of the IMI Spectrum later this year,” said Jorey Chernett, CEO of Intrinsic Medical Imaging. “Engaging clinicians throughout the development process is core to our commercialization strategy and clinical feedback has been extremely positive on the potential of the IMI Spectrum technology. Intrinsic has attracted a highly accomplished team with deep domain expertise focused on revolutionizing 3D medical imaging.”

Intrinsic Medical Imaging is a medical software company focused on the marketing of high-performance rendering techniques. The IMI Spectrum workstation, built around IMI’s Authentic 3D software, is an imaging system that enables the real-time processing, review, and analysis of volumetric data generated by conventional CT scanners.

Related Links:
Intrinsic Medical Imaging